Close

India Globalization Capital, Inc. (IGC) Announces Update On Phase 1 Clinical Trial on Alzheimer's Patients

Go back to India Globalization Capital, Inc. (IGC) Announces Update On Phase 1 Clinical Trial on Alzheimer's Patients

Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients

February 22, 2021 8:00 AM EST

POTOMAC, Md.--(BUSINESS WIRE)-- India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) is pleased to announce the progress of its tetrahydrocannabinol (THC)-based phase 1 clinical trial, which was approved to proceed by the U.S. Food and Drug Administration (FDA) on July 30, 2020, as previously disclosed.

On February 11, 2021, the Company completed administering the first of three levels of dosing of IGC-AD1, the Companys cannabinoid-based investigational new drug, on the first five of twelve patients suffering from Alzheimers disease. The Company continues to enroll the remaining patients.

Enrolling patients and... More